<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494882</url>
  </required_header>
  <id_info>
    <org_study_id>14-272</org_study_id>
    <nct_id>NCT02494882</nct_id>
  </id_info>
  <brief_title>Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older</brief_title>
  <official_title>Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of a new combination of three oral drugs in&#xD;
      Ph+ ALL. These drugs are dexamethasone, dasatinib, and ruxolitinib. All three drugs have been&#xD;
      studied before in humans.&#xD;
&#xD;
      This is a phase I study in which ruxolitinib dose will start low for the first patient&#xD;
      together with dexamethasone plus dasatinib. If this dose does not cause a bad side effect,&#xD;
      the ruxolitinib dose will slowly be made higher as new patients take part in the study. This&#xD;
      will help the investigators find the right dose of ruxolitinib to give together with&#xD;
      dexamethasone and dasatinib that will be used in future studies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 29, 2015</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>2 years</time_frame>
    <description>is to be evaluated by using a combination of criteria. Molecular remissions will be defined by standard criteria for BCR-ABL1 and IGH qRT-PCR. Flow cytometric assessment of MRD will be defined by standard flow cytometry criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Molecular Remission (CMR) rate</measure>
    <time_frame>2 years</time_frame>
    <description>Molecular remission status will be defined by undetectable BCR-ABL1 transcripts and/or IGH clonal gene rearrangement in bone marrow aspirate (BMA) examination as determined by qRT-PCR in CLIA laboratory.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Adding Ruxolitinib to Combination of Dasatinib + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Steroid Pre-Phase (Days -6 to 0) Prednisone 10 mg/m2/day uptitrated to 60/mg/m2/day oral over seven days (capped at 120 mg/day).&#xD;
Remission Induction (Days 1 to 84) Dasatinib 140 mg oral once daily. Days 1-84. Dexamethasone 10 mg/m2/day oral (capped at 20 mg/day). Days 1-24. Dexamethasone oral taper 10 mg/m2/day (capped at 20 mg/day) to off. Taper days 25-32. Off day 33.&#xD;
Ruxolitinib phase I cohort dose oral. Days 1-84. Delivered BID. Delivered per the phase I dose cohort. Methotrexate (MTX) 12 mg Intrathecal (IT) for 4 doses on days 22, 43, 64, 85; +/- 3 days.&#xD;
Post-Remission Induction Therapy (Starting Day 85) Allogeneic HSCT, at the discretion of the treating physician, at any point post-remission induction.&#xD;
Or, post-remission induction (consolidation) therapy to be determined per the treating physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <arm_group_label>Adding Ruxolitinib to Combination of Dasatinib + Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <arm_group_label>Adding Ruxolitinib to Combination of Dasatinib + Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Adding Ruxolitinib to Combination of Dasatinib + Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient able to give informed consent.&#xD;
&#xD;
          -  Patients &gt;/= 18 years with the following disease will be eligible&#xD;
&#xD;
               -  Newly diagnosed Ph+ ALL, previously untreated, except for the below allowances&#xD;
&#xD;
               -  Previously received HpyerCVAD cycle 1A+/- cycle 1B&#xD;
&#xD;
               -  Previously received Induction Phase 1 +/- Induction Phase II of BFM-modeled&#xD;
                  (Pediatric of Pediatric-Inspired) ALL regimen&#xD;
&#xD;
               -  Previously received other representative (modified from HyperCVAD, BFM, or&#xD;
                  AML-like) ALL induction course, including ABL TKI plus corticosteroid.&#xD;
&#xD;
               -  If the patient has received any of the above prior therapy, they may be enrolled,&#xD;
                  regardless of remission status.&#xD;
&#xD;
               -  Relapsed PH+ ALL, with no prior exposure to dasatinib and without known ABL&#xD;
                  kinase mutations predited to be resistant to dasatibin (e.g. L248R, L248V, Q252H,&#xD;
                  E255K, V299L, T315A, T315I, F317C, F317L, F317S, F317V)&#xD;
&#xD;
               -  Relapsed or refractory Ph-like ALL without prior exposure to dasatibin and with&#xD;
                  mutations or rearrangements of genes conferring sensitivity to dasatibin (ABL,&#xD;
                  CSF1R, PDGFRB) or ruxolitinib (CRLF2, JAK3, EPOR, TSLP)&#xD;
&#xD;
               -  Newly diagnosed or relapsed CML in lymphoid blast crisis&#xD;
&#xD;
          -  Confirmation of Philadelphia chromosome positivity by cytogenetics (karyotype/FISH)&#xD;
             and/or molecular tests (BCR-ABL1 transcripts)&#xD;
&#xD;
          -  Acceptable end-organ function, except for documented exclusions for organ function&#xD;
             compromise due to ALL itself&#xD;
&#xD;
          -  ECOG performance status â‰¤ 2&#xD;
&#xD;
          -  Men and women of childbearing potential must be willing to practice an effective&#xD;
             method of birth control during treatment and for at least 4 months following treatment&#xD;
             on study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ph-negative ALL&#xD;
&#xD;
          -  Patients with dominant leukemic clone bearing documented bcr-abl mutations enabling&#xD;
             bcr-abl TKI resistance at diagnosis&#xD;
&#xD;
          -  Mature B-cell (Burkitt's) ALL&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5x ULN and calculated creatinine clearance, based on a 24-hour&#xD;
             urine collection, &lt; 30 mL/min--unless related to ALL/tumor lysis syndrome and able to&#xD;
             be corrected&#xD;
&#xD;
          -  Direct Bilirubin &gt; 2x ULN; AST/ALT &gt; 10x ULN, unless related to ALL liver&#xD;
             infiltration.&#xD;
&#xD;
          -  Pregnant women or women who are breast-feeding&#xD;
&#xD;
          -  Patients with HIV, Hepatitis B, or Hepatitis C&#xD;
&#xD;
          -  Pre-treatment QTcF &gt; 480 msecs&#xD;
&#xD;
          -  A &quot;washout&quot; period of at least 14 days from last previous cytotoxic chemotherapy will&#xD;
             be required prior to starting treatment on this protocol. No &quot;washout&quot; period will be&#xD;
             required for previous bcr-abl TKI therapy given with the aforementioned previous&#xD;
             chemotherapy cycles. Hydroxyurea and corticosteroids may be given as bridge therapy up&#xD;
             until 24 hours prior to initiating protocol treatment.&#xD;
&#xD;
          -  Active malignancy requiring treatment other than ALL within two years prior to start&#xD;
             of treatment, with the exception of basal cell or squamous cell carcinoma of the skin,&#xD;
             carcinoma in situ of the cervix, localized prostate cancer, or DCIS or LCIS of the&#xD;
             breast&#xD;
&#xD;
          -  Active, uncontrolled infection, any other concurrent disease, or medical condition&#xD;
             that is deemed to interfere with the conduct of the study as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  Unable to tolerate anti-viral and anti- Pneumocystis jirovecii prophylaxis while on&#xD;
             pre-phase and remission induction therapy&#xD;
&#xD;
          -  Unable to tolerate gastrointestinal prophylaxis therapy with sucralfate while on&#xD;
             pre-phase and remission induction therapy. Or severe pre-existing GI disorder that&#xD;
             requires PPI or H2 receptor antagonist therapy be uninterrupted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ruxolitinib</keyword>
  <keyword>Dasatinib</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>14-272</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

